VBLT News

11 IPOs priced during the week of September 29, but only 3 had any meaningful gains, including two tech deals and American Addiction Centers, a network of substance abuse treatment centers. The group raised $2.4 billion; 25% less than expected after frac sand maker Fairmount Santrol cut its deal size 60% to just $400 million. Fairmount was one of five offerings with private equity...read more

Vascular Biogenics, which is developing gene therapies for cancer and small molecules for inflammation, raised $40 million by offering 6.7 million shares at $6, below the range of $13 to $15. Insiders planned to purchase 4.0 million shares (60% of the deal). Vascular Biogenics, which does business as VBL Therapeutics, previously priced its IPO at $12 per share on July 30, 2014, but...read more

Vascular Biogenics, which is developing gene therapies for cancer and small molecules for inflammation, raised $65 million by offering 5.4 million shares at $12, below the range of $13 to $15. Vascular Biogenics plans to list on the NASDAQ under the symbol VBLX. Vascular Biogenics initially filed confidentially on 3/25/2014. Deutsche Bank and Wells Fargo Securities acted as lead...read more

Vascular Biogenics, a biotech developing gene therapies for certain cancers and inflammatory diseases, announced terms for its IPO on Wednesday. The Or Yehuda, Israel-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $282 million. ...read more